Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know. Gilead Sciences beat analysts’ revenue expectations by 3.7% ...

What a time it’s been for Exact Sciences. In the past six months alone, the company’s stock price has increased by a massive ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

On 20 January 2026, Ropes & Gray’s Global Life Sciences Regulatory & Compliance team hosted the “Life Sciences Regulatory Outlook 2026” webinar.

Achieve Life Sciences is a late-stage pharma company awaiting FDA approval for Cytisinicline, a novel smoking cessation ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...